» Authors » Jamila Hamdani

Jamila Hamdani

Explore the profile of Jamila Hamdani including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 106
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Bizimungu C, Sabbe M, Wuillaume F, Hamdani J, Koch P, Dogne J
Vaccines (Basel) . 2023 May; 11(5). PMID: 37243058
The rapid and large-scale roll-out of new COVID-19 vaccines has led to unprecedented challenges in assessing vaccine safety. In 2021, the European Medicines Agency (EMA) processed about 1.7 million safety...
2.
Pochet S, Lechon A, Lescrainier C, De Vriese C, Mathieu V, Hamdani J, et al.
Sci Rep . 2022 Aug; 12(1):14178. PMID: 35986023
Cancer patients could combine herbal treatments with their chemotherapy. We consulted VigiBase, a WHO database of individual case safety reports (ICSRs) which archives reports of suspected Adverse Drug Reactions (ADRs)...
3.
Sabbe M, Sawchik J, Grafe M, Wuillaume F, de Bruyn S, Van Antwerpen P, et al.
Arch Public Health . 2022 Feb; 80(1):54. PMID: 35168683
Background: Misuse of prescription stimulants (PS) has been reported among students to enhance academic performance in Flanders (Belgium). However, PS misuse among students in the French-speaking community is unknown. The...
4.
Themans P, Belkhir L, Dauby N, Yombi J, De Greef J, Delongie K, et al.
Eur J Drug Metab Pharmacokinet . 2020 Sep; 45(6):703-713. PMID: 32968954
Background And Objective: In the absence of characterization on pharmacokinetics and reference concentrations for hydroxychloroquine in COVID-19 patients, the dose and treatment duration for hydrochloroquine are currently empirical, mainly based...
5.
Themans P, Dauby N, Schrooyen L, Lebout F, Delforge M, Nasreddine R, et al.
Br J Clin Pharmacol . 2020 Jun; 87(2):674-682. PMID: 32559820
Aims: In the absence of a commonly agreed dosing protocol based on pharmacokinetic (PK) considerations, the dose and treatment duration for hydroxychloroquine (HCQ) in COVID-19 disease currently vary across national...
6.
Lelubre M, Hamdani J, Senterre C, Amighi K, Peres M, Schneider M, et al.
Pharmacoepidemiol Drug Saf . 2018 May; 27(6):668-673. PMID: 29726056
Purpose: To evaluate awareness of and compliance in Belgium by French-speaking health care professionals and patients with the isotretinoin safety recommendations regarding its teratogenic risk. Method: Survey using online questionnaires,...
7.
de Fays L, Van Malderen K, De Smet K, Sawchik J, Verlinden V, Hamdani J, et al.
Dev Med Child Neurol . 2015 Apr; 57(8):718-24. PMID: 25851072
Paracetamol (acetaminophen) remains the first line for the treatment of pain and fever in pregnancy. Recently published epidemiological studies suggested a possible association between paracetamol exposure in utero and attention-deficit-hyperactivity...
8.
Hamdani J, Moes A, Amighi K
Int J Pharm . 2006 Jul; 322(1-2):96-103. PMID: 16824707
The feasibility of preparing floating pellets by melt pelletization was investigated. The pellets were prepared in a high shear mixer. Formulations were based on a mixture of Compritol and Precirol...
9.
Hamdani J, Moes A, Amighi K
Int J Pharm . 2003 Jun; 260(1):47-57. PMID: 12818809
Physical and thermal properties of Compritol and Precirol as potential lipophilic binders in melt pelletisation process for the preparation of sustained-release matrix pellets were evaluated in this study. Experimental measurements...
10.
Hamdani J, Moes A, Amighi K
Int J Pharm . 2002 Sep; 245(1-2):167-77. PMID: 12270253
This study was performed in order to evaluate the possibility of obtaining prolonged release matrix pellets by a melt pelletization process in a laboratory high shear mixer (Mi-Pro, Pro-C-epT). Phenylephrine...